Pfizer's radical R&D cutbacks to continue in 2013

Pfizer ($PFE) may be a bit behind schedule, but it's on track to hack its R&D budget to the $6.5 billion-to-$7 billion target laid out in a radical restructuring plan. The company's research spending dropped to $7.8 billion in 2012, down from $9.4 billion in 2010. Another $1.3 billion is on the chopping block this year. Report

Suggested Articles

Johnson & Johnson faces a litany of problems, but executives are clearly not concerned—at least not about the company's short-term fortunes.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

CMS has determined how it'll pay for Gilead's CAR-T cancer therapy, Yescarta, for outpatient use, but hasn't yet decided on Gilead's…